Guy P. Sansone - 04 Jan 2022 Form 4 Insider Report for MAGELLAN HEALTH INC

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 04 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jan 2022, 16:21:20 UTC
Prior SEC filing: 13 Aug 2021
Next SEC filing: 14 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Guy P. Sansone

Key filing fact

Guy P. Sansone filed Form 4 for MAGELLAN HEALTH INC on 04 Jan 2022.

Key facts

This page summarizes Guy P. Sansone's Form 4 filing for MAGELLAN HEALTH INC.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Jan 2022, 16:21.

Change

Previous filing in this sequence was filed on 13 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MGLN transaction

Ordinary Common Stock, $0.01 par value

Disposed to Issuer

Transaction value: $0
Shares: -7,973
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 04 Jan 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuers common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration").

Footnote F2

Includes 2,911 restricted shares of Common Stock. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each of these restricted shares of Common Stock was automatically cancelled and converted into the right to receive the Merger Consideration.